Claims
- 1. An immunotoxin, comprising a mutant diphtheria toxin moiety linked to a single chain variable region antibody which routes by the anti-CD3 pathway, or derivatives thereof.
- 2. The immunotoxin of claim 1, wherein the antibody is divalent.
- 3. The immunotoxin of claim 1, wherein the immunotoxin is a fusion protein.
- 4. The immunotoxin of claim 1, wherein the antibody comprises the UCHT1 VLVH region.
- 5. The immunotoxin of claim 4, wherein the antibody comprises human CH2 and CH3 regions.
- 6. The immunotoxin of claim 5, wherein the antibody is divalent scUCHT1.
- 7. The immunotoxin of claim 6, wherein the immunotoxin is a fusion protein.
- 8. The immunotoxin of claim 7, wherein the immunotoxin is is scUCHT1-DT390.
- 9. A method of treating an autoimmune disease in an animal comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof, under conditions such that the autoimmune disease is treated.
- 10. The method of claim 8, wherein the non-toxic mutant of diphtheria toxin moiety is DT390.
- 11. The method of claim 8, wherein the antibody moiety scUCHT1.
- 12. A method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
- 13. The method of claim 11, wherein the non-toxic mutant of diphtheria toxin is DT390.
- 14. The method of claim 11, wherein the antibody moiety scUCHT1.
- 15. A method of treating graft-versus-host disease in an animal, comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof under conditions such that the graft-versus-host disease is treated.
- 16. The method of claim 14, wherein the non-toxic mutant of diphtheria toxin is DT390.
- 17. The method of claim 14, wherein the antibody moiety scUCHT1.
- 18. A method of treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated.
- 19. The method of claim 17, wherein the non-toxic mutant of diphtheria toxin is DT390.
- 20. The method of claim 17, wherein the antibody moiety scUCHT1.
Parent Case Info
[0001] This application for letters patent claims priority under 35 U.S.C. § 119(e) of provisional patent application Ser. No. 60/008,104, filed on Oct. 30, 1995, having the same title of invention and the same inventors (as added by amendment to correct inventorship filed Sep. 11, 1996) as the present application.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60008104 |
Oct 1995 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08739703 |
Oct 1996 |
US |
Child |
09389565 |
Sep 1999 |
US |